NHI.no
Annonse
Informasjon

Kawasakis sykdom

Kawasakis sykdom er en febersykdom hos barn med utslett, slimhinneforandringer, øyekatarr, lymfeknuteforstørrelse på halsen og hudforandringer i fotsåler og håndflater. Tilstanden er selvbegrensende, men ubehandlet utvikles det hos 20-25 prosent utposninger på kransårene i hjertet.

Symptomene på Kawasakis syndrom kan variere noe, men alle har feber i mer enn fem dager.

Sist oppdatert:

8. juli 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Kawasakis sykdom . Referanselisten for dette dokumentet vises nedenfor

  1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135: e927. pmid:28356445 PubMed
  2. Rypdal V, Songstad NT, Nyrnes SA, et al. Kawasakis sykdom. Akuttveileder i pediatri. Sist revidert 2021. www.helsebiblioteket.no
  3. Saguil A, Fargo M, Grogan S.Diagnosis and management of Kawasaki disease. Am Fam Physician 2015 Mar 15;91(6):365-371.
  4. Roed C, Skinhøj P. Kawasakis syndrom hos voksne. Ugeskr Læger 2009; 171: 430. Ugeskrift for Læger
  5. Brogan P, Burns JC, Cornish J, et al. Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart 2019. pmid:31843876 PubMed
  6. Harnden A,Tulloh R, Burgner D. Kawasaki disease. BMJ. 2014 Sep 17;349:g5336. doi: 10.1136/bmj.g5336 DOI
  7. Wang H, Shimizu C, Bainto E, et al. Subgroups of children with Kawasaki disease: a data-driven cluster analysis. Lancet Child Adolesc Health 2023. pmid:37598693 PubMed
  8. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020. doi:10.1016/ S0140-6736(20)31103-X
  9. Yellen ES, Gauvreau K, Takahasi M, et. al. Performance of 2004 American Heart Association Recommendations for Treatment of Kawasaki Disease. Pediatrics 2010; 125: 234-41. Pediatrics
  10. Chen S et al. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-analysis. JAMA Pediatr 2016; 170: 1156-63. PubMed
  11. Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 2019. pmid:30853151 PubMed
  12. Ferrara G et al. Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review. Paediatr Drugs 2020; 22: 645-52. PubMed
  13. Platt B, Belarski E, Manaloor J, et al. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. JAMA Netw Open 2020; 3: e1918565. pmid:31899532 PubMed
  14. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; doi:10.1016/S0140-6736(11)61930-2. DOI
  15. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2012. pmid:22869678 PubMed
  16. Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017 Jan 27;1:CD011188. PMID: 28129459 PubMed
  17. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double blind, placebo-controlled trial. Lancet 2014. doi:10.1016/S0140-6736(13)62298-9 DOI
  18. Zhao QM, Chu C, Wu L, et al. Systemic Artery Aneurysms and Kawasaki Disease. Pediatrics 2019. pmid:31732547 PubMed
Annonse
Annonse